Answers are grounded in this paper and cite their sources.
Marburg variant of multiple sclerosis (MS) is a rare, fulminant demyelinating disorder characterized by rapid neurological decline and notable lack of established standardized treatment guidelines. We describe a 46-year-old woman presenting with progressive cognitive and behavioral changes and multifocal CNS lesions initially refractory to corticosteroids, plasmapheresis (PLEX), and intravenous immunoglobulin (IVIg). Brain biopsy confirmed aggressive MS-spectrum demyelination. Escalation to high-dose cyclophosphamide resulted in radiologic stabilization but was limited by severe, refractory cytopenia. Given persistent disease activity and intolerance to infusion-based therapy, transition from ocrelizumab to subcutaneous ofatumumab was planned as a pragmatic maintenance strategy; however, treatment initiation was delayed. The patient subsequently experienced rapid clinical deterioration marked by recurrent aspiration events and functional decline, ultimately leading to death following transition to comfort-focused care. This case highlights the therapeutic challenges of Marburg MS, including treatment-limiting toxicity, logistical barriers to anti-CD20 therapy, and the critical importance of timely, individualized immunosuppressive strategies.
No takes yet. Share an insight, caveat, or question.
Bhattarai et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: